<DOC>
	<DOCNO>NCT01512979</DOCNO>
	<brief_summary>The purpose trial determine whether initial combination linagliptin metformin compare linagliptin alone 24 week effective newly diagnose , treatment-naïve patient Type 2 Diabetes .</brief_summary>
	<brief_title>Linagliptin Metformin Versus Linagliptin Newly Diagnosed , Untreated Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients must sign date Informed Consent consistent International Conference Harmonisation / Good Clinical Practice guideline local regulation prior evaluation participation trial . 2 . Male female patient , 18 year age old Visit 1 ( Screen ) , newly diagnose ( less 12 month prior Screen ) Type 2 Diabetes Mellitus . 3 . Patients treatmentnaïve , define absence oral antidiabetic therapy , injectable glucagonlike peptide1 agonist/analogue , insulin , uncontrolled 12 week prior randomisation . 4 . Patients must glycated ( glycosylated ) haemoglobin ( HbA1c ) 8.5 % [ 69 millimoles per mole ( mmol/mol ) ] 12.0 % ( 108 mmol/mol ) Visit 1 ( Screen ) . 5 . Patients must Body Mass Index ( BMI ) 45 kg/m2 less Visit 1 ( Screen ) . 6 . In investigator opinion , patient must reliable , honest , compliant , agree cooperate plan future trial evaluation explain detail inform consent process able perform . Exclusion criterion : Patients , , , : 1 . Acute coronary syndrome ( nonST Elevation Myocardial Infarction ( STEMI ) , STEMI , unstable angina pectoris ) , stroke transient ischemic attack within 3 month prior inform consent . 2 . Indication liver disease determine Screen and/or RunIn Period , define serum level 3 time upper limit normal ( ULN ) following : alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase . GilbertMeulengracht syndrome ( also know conjugated hyperbilirubinemia , constitutional hepatic dysfunction , familial nonhemolytic jaundice ) permit . 3 . Impaired renal function , define calculated creatinine clearance le 60 milliliter per minute ( &lt; 60 mL/min ) , CockcroftGault Equation , determine Screen and/or RunIn Period . 4 . Bariatric , gastric bypass , gastrointestinal surgery ( include type gastric band and/or LapBand ) within past two year . 5 . Medical history cancer ( except basal cell carcinoma ) and/or treatment cancer within last 5 year . 6 . Medical history pancreatitis . 7 . Blood dyscrasia disorder cause hemolysis unstable red blood cell ( e.g. , malaria , babesiosis , haemolytic anaemia ) . 8 . Any contraindication metformin and/or linagliptin therapy , accord local label . 9 . Treatment antiobesity drug , include overthecounter drug Alli ( orlistat ) , 3 month prior inform consent treatment time screen ( i.e. , surgery , aggressive diet regimen , etc . ) lead unstable body weight . 10 . Current treatment systemic steroid time informed consent change dosage thyroid hormone within 6 week prior inform consent uncontrolled endocrine disorder except Type 2 Diabetes Mellitus . 11 . Premenopausal woman ( last menstruation 1 year less prior informed consent ) nursing pregnant , childbearing potential practicing acceptable method birth control , plan continue use method throughout trial agree submit periodic pregnancy test participation trial . Note : Acceptable method birth control include tubal ligation , transdermal patch , intra uterine devices/systems , oral , implantable , intravaginal , injectable contraceptive , Essure microinserts place six month prior Screen Visit , complete sexual abstinence ( acceptable local authority ) , double barrier method ( e.g. , diaphragm condom spermicide ) , vasectomise partner . 12 . Alcohol drug abuse within 3 month prior inform consent would interfere trial participation ongoing condition lead decrease compliance trial procedure study medication intake opinion investigator . 13 . Participation another trial investigational drug within 2 month prior inform consent . 14 . Any clinical condition would jeopardize patient safety participate clinical trial opinion Investigator . 15 . Inability commit regular overnight fast least 10 hour duration attendance study site visit 07:00 11:00 ante meridiem ( a.m. ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>